| Date | Title | Description |
| 29.10.2024 | AbbVie’s Bold Move: Acquiring Aliada Therapeutics for CNS Breakthroughs | In a strategic maneuver that echoes the age-old adage, "the early bird catches the worm," AbbVie has set its sights on the burgeoning field of central nervous system (CNS) therapeutics. The Chicago-based pharmaceutical giant annou... |
| 29.10.2024 | Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics | SAN FRANCISCO and SUZHOU, China, Oct. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 19.10.2024 | The Dawn of a New Era in Drug Discovery: Sanyou Bio's Super-Trillion Molecule Library | In the bustling heart of Shanghai, a revolution is brewing in the world of pharmaceuticals. Sanyou Bio, under the visionary leadership of Lang Guojun, has unveiled a groundbreaking innovation: the super-trillion molecule library. This monum... |
| 17.10.2024 | Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint | SAN FRANCISCO and SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 08.10.2024 | Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer | SAN FRANCISCO and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 08.10.2024 | Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC | ROCKVILLE, Md. and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily f... |
| 01.10.2024 | Innovent's Picankibart: A New Dawn for Psoriasis Treatment in China | In the ever-evolving landscape of biopharmaceuticals, Innovent Biologics has emerged as a beacon of hope for millions suffering from moderate to severe plaque psoriasis. The company recently announced that its New Drug Application (NDA) for... |
| 26.09.2024 | Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis | SAN FRANCISCO and SUZHOU, China, Sept. 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 19.09.2024 | Innovent Biologics: Pioneering New Frontiers in Cancer Treatment | In the world of oncology, the quest for effective treatments is relentless. Innovent Biologics, a biopharmaceutical company based in China, is at the forefront of this battle. Recently, they presented groundbreaking clinical data at the 202... |
| 18.09.2024 | Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress | SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 18.09.2024 | Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 202... | SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 14.09.2024 | Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation | ROCKVILLE, Md. and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily... |
| 12.09.2024 | Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024 | SAN FRANCISCO and SUZHOU, China, Sept. 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatme... |
| 11.09.2024 | Pioneering Cancer Treatments Take Center Stage at ESMO 2024 | The European Society of Medical Oncology (ESMO) Congress 2024 is set to be a pivotal event in the world of oncology. From September 13 to 17, Barcelona will host a gathering of minds, all focused on the latest breakthroughs in cancer treatm... |
| 11.09.2024 | Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC | SAN FRANCISCO and SUZHOU, China, Sept. 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 10.09.2024 | Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation | SAN FRANCISCO and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 09.09.2024 | ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress | ROCKVILLE, Md. and SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malign... |
| 04.09.2024 | Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma | SAN FRANCISCO and SUZHOU, China, Sept. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 02.09.2024 | Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024 | SAN FRANCISCO and SUZHOU, China, Sept. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 29.08.2024 | Innovent and Lilly: Pioneering Paths in Biopharmaceuticals | In the ever-evolving landscape of biopharmaceuticals, two companies stand out: Innovent Biologics and Eli Lilly. Both are making waves, each with a unique approach to tackling pressing health issues. Innovent, based in Suzhou, China, is car... |
| 29.08.2024 | Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024 | SAN FRANCISCO and SUZHOU, China, Aug. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 28.08.2024 | A New Dawn in Lung Cancer Treatment: GenFleet's KRAS G12C Inhibitor Approved in China | In a groundbreaking move for cancer treatment, GenFleet Therapeutics has received approval from China's National Medical Products Administration (NMPA) for its KRAS G12C inhibitor, Dupert® (fulzerasib). This marks a significant milestone in... |
| 28.08.2024 | Innovent Announces 2024 Interim Results and Business Updates | Strong commercial performance and significant pipeline milestones
support sustained growth and innovation
SAN FRANSISCO and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopha... |
| 28.08.2024 | Innovent Announces 2024 Interim Results and Business Updates | Strong commercial performance and significant pipeline milestones
support sustained growth and innovation
SAN FRANSISCO and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopha... |
| 23.08.2024 | GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation | SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's National Medical Products Administration has approved Dup... |
| 22.08.2024 | China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China | SAN FRANCISCO and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 13.08.2024 | Registrational Phase III Study of Lisaftoclax in Newly-Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome Cleared by China CDE | ROCKVILLE, Md. and SUZHOU, China, Aug. 13, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for ma... |
| 03.08.2024 | Innovent's Dual Approach to Diabetes and Hypertension: A New Era in Treatment | In the bustling world of biopharmaceuticals, Innovent Biologics is making waves. With two significant announcements in August 2024, the company is positioning itself as a key player in the treatment of chronic diseases like type 2 diabetes ... |
| 02.08.2024 | Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA) | SAN FRANSCISO and SUZHOU, China, Aug. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 01.08.2024 | Innovent Announces the NDA of Mazdutide for Type 2 Diabetes has been Accepted by the NMPA of China | SAN FRANCISCO, U.S. and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 26.07.2024 | Advancing Dermatological Research: The American Skin Association's 2024 Grants**
** | ** The American Skin Association (ASA) has taken a bold step forward in the fight against skin diseases. On July 22, 2024, the ASA announced its 2024 research grants, a lifeline for scientists dedicated to understanding and treating skin co... |
| 26.07.2024 | BioVaxys and Innovent: Pioneering New Frontiers in Immunotherapy and Diabetes Treatment**
** | ** In the ever-evolving landscape of biopharmaceuticals, two companies are making waves: BioVaxys Technology Corp. and Innovent Biologics. Each is tackling significant health challenges with innovative approaches. BioVaxys is focused on imm... |
| 26.07.2024 | Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development | SAN FRANCISCO and SUZHOU, China, July 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 22.07.2024 | Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA | SAN FRANCISCO and SUZHOU, China, July 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 08.07.2024 | Innovent Launches Environmental, Social and Governance (ESG) Website to Advance Sustainability and Corporate Responsibility | SAN FRANCISCO and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Environmental, Social and Governance (ESG) criteria are key indicators of a company's long-term sustainability. Innovent Biologics has been actively addressing the United Nations... |
| 08.07.2024 | Olverembatinib Approved for Commercialization in Macau China | ROCKVILLE, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for hematological m... |
| 05.07.2024 | IASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy | SHANGHAI and NANJING, China and SAN JOSE, Calif., July 5, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies... |
| 05.07.2024 | Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy | SAN FRANCISCO and SUZHOU, China, July 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 04.07.2024 | Ascentage Pharma Received US$100 Million Option Payment from Takeda | ROCKVILLE, Md. and SUZHOU, China, July 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematol... |
| 02.07.2024 | Innovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junctio... | SAN FRANCISCO and SUZHOU, China, July 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 28.06.2024 | Innovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine Pipeline | SAN FRANCISCO and SUZHOU, China, June 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 25.06.2024 | Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024 | SAN FRANCISCO and SUZHOU, China, June 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 25.06.2024 | Innovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions | SAN FRANCISCO and SUZHOU, China, June 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 21.06.2024 | Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform | BEIJING, June 21, 2024 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully ... |
| 19.06.2024 | Innovent Reports Oncology Pipeline Updates at Investor Meeting | SAN FRANCISCO and SUZHOU, China, June 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 18.06.2024 | Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including Encouraging Data from US Study in CML and Ph+ ALL | SUZHOU, China and ROCKVILLE, Md., June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| 14.06.2024 | Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the ... | SAN FRANCISCO and SUZHOU, China, June 14, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 13.06.2024 | Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer | SAN FRANCISCO and SUZHOU, China, June 13, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 12.06.2024 | Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions | SAN FRANCISCO and SUZHOU, China, June 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 11.06.2024 | Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE | SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced... |
| 05.06.2024 | Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% | SUZHOU, China and ROCKVILLE, Md., June 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced t... |
| 03.06.2024 | Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatme... | SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 03.06.2024 | Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer a... | SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 02.06.2024 | Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting | SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 02.06.2024 | Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 02.06.2024 | Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 02.06.2024 | Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 28.05.2024 | Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA | SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 27.05.2024 | Chinese regulators greenlight Eli Lilly’s tirzepatide diabetes drug | On May 21, the National Medical Products Administration (NMPA) announced that Eli Lilly’s diabetes drug tirzepatide has been approved for the Chinese market. The approved indication is specifically for blood glucose control in adult patient... |
| 27.05.2024 | Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA | SAN FRANCISCO and SUZHOU, China, May 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 21.05.2024 | Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease | SAN FRANCISCO and SUZHOU, China, May 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 20.05.2024 | Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC) | SAN FRANCISCO and SUZHOU, China, May 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 09.05.2024 | Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints | SAN FRANCISCO and SUZHOU, China, May 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment ... |
| 07.05.2024 | Innovent Receives NMPA Breakthrough Therapy Designation for IBI343（Anti-Claudin18.2 ADC）as Monotherapy for Advanced Gastric Cancer | SAN FRANCISCO and SUZHOU, China, May 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for th... |
| 06.05.2024 | Innovent Receives NMPA Breakthrough Therapy Designation for IBI343（Anti-Claudin18.2 ADC）as Monotherapy for Advanced Gastric Cancer | SAN FRANCISCO and SUZHOU, China, May 6, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for th... |
| 30.04.2024 | Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO) | SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 25.04.2024 | Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting | SAN FRANCISCO and SUZHOU, China, April 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 16.04.2024 | Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO) | SAN FRANCISCO and SUZHOU, China, April 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 08.04.2024 | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 02.04.2024 | Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status | ROCKVILLE, Md. and SUZHOU, China, April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 27.03.2024 | Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy | ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
| 20.03.2024 | Innovent Announces 2023 Annual Results and Business Updates | A transformative year of strong performance and material innovation progress
ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that d... |
| 20.03.2024 | Innovent Announces 2023 Annual Results and Business Updates | A transformative year of strong performance and material innovation progress
ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that d... |
| 19.03.2024 | Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD) | ROCKVILLIE, Md. and SUZHOU, China, March 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines f... |
| 12.03.2024 | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
| 07.03.2024 | Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congr... | ROCKVILLIE, Md. and SUZHOU, China, March 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
| 05.03.2024 | Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer | ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 01.03.2024 | Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia | ROCKVILLE, Md. and SUZHOU, China, March 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatme... |
| 20.02.2024 | Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA | ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
| 07.02.2024 | Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China | ROCKVILLE, Md. and SUZHOU, China, Feb. 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 22.11.2023 | Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care | ROCKVILLE, Md.and SUZHOU,China, Nov. 22, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment... |
| 06.11.2023 | Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023 | ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 30.10.2023 | Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity | Mazdutide demonstrates its differentiated advantages as a novel dual agonist of GLP-1 and GCG receptor with superior weight loss efficacy, significant improvement in a series of cardiometabolic indicators (waist circumference, blood pressur... |
| 28.09.2023 | IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023 | 82.4% of patients without prior CAR-T achieving Complete Response (CR) or better
SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 28, 2023 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manu... |
| 26.06.2023 | Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China | ROCKVILLE, Md. and SUZHOU, China, June 26, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 12.06.2023 | Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, June 12, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 06.06.2023 | Promising 2-year updated data from cadonilimab presented at 2023 ASCO highlighting promising efficacy in PD-L1-negative patients | HONG KONG, June 6, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso") released two-year updated data from a Phase Ib/II clinical study of cadonilimab – a first-in-class PD-1/CTLA-4 bispecific antibody developed by Akeso – in com... |
| 06.06.2023 | Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, June 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 05.06.2023 | Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 03.06.2023 | Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST | ROCKVILLE, Md. and SUZHOU, China, June 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 02.06.2023 | Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCL... | ROCKVILLE, Md. and SUZHOU, China, June 2, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 17.05.2023 | Innovent Announces Clinical Data of Multiple Trials Will be Presented at the 2023 ASCO and EHA Annual Meetings | ROCKVILLE, Md. and SUZHOU, China, May 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 15.05.2023 | Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma | ROCKVILLE, Md. and SUZHOU, China, May 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 10.05.2023 | The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy | ROCKVILLIE, Md. and SUZHOU, China, May 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 08.05.2023 | Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer ... | ROCKVILLE, Md. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 08.05.2023 | Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease | ROCKVILLE, MD. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 20.04.2023 | Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023 | ROCKVILLE, Md. and SUZHOU, China, April 20, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
| 18.04.2023 | Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023 | ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
| 18.04.2023 | Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRAS[G12C] Inhibitor) as Monotherapy for Solid Tumors at the AACR Annual Meeting 2023 | ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
| 17.04.2023 | Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2... | ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
